Richey William Drake 4
4 · Tempest Therapeutics, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Tempest (TPST) Director Richey Drake Receives 25,000-Unit Award
What Happened
Richey William Drake, a director of Tempest Therapeutics, was granted a derivative award of 25,000 shares on 2026-06-04. The filing lists the acquisition price as $0.00 and classifies the transaction as an award/grant (code A). The filing’s footnote characterizes these awards as stock options and specifies a multi-year vesting schedule.
Key Details
- Transaction date: 2026-06-04; Filing date: 2026-06-08.
- Award: 25,000 derivative shares (reported at $0.00).
- Vesting: 3-year schedule — one-third vests on the first anniversary, remainder vests in equal monthly installments thereafter, subject to continued service (per footnote).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Transaction type: Award/Grant (A). No sale or exercise reported.
- Timeliness: filing occurred four days after the grant (you may compare to the SEC’s two-business-day Form 4 deadline).
Context
This was a grant of derivative securities (the filing’s footnote identifies them as stock options) that vest over time; it does not represent an immediate cash purchase or sale. Such awards are common for directors and are typically intended to align long-term incentives; they do not by themselves signal an intent to buy or sell shares in the open market.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-04+25,000→ 25,000 totalExercise: $1.27Exp: 2036-06-04→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.